Bulsei Julie, Chierici Andrea, Alifano Marco, Castaldi Antonio, Drai Céline, De Fatico Serena, Rosso Edoardo, Fontas Eric, Iannelli Antonio
Centre Hospitalier Universitaire de Nice, Department of Clinical Research and Innovation, Université Côte d'Azur, Nice, France.
Service de Chirurgie Digestive, Centre Hospitalier d'Antibes Juan-les-Pins, 107, av. de Nice, 06600, Antibes, France.
Eur J Surg Oncol. 2023 Apr;49(4):788-793. doi: 10.1016/j.ejso.2022.11.013. Epub 2022 Nov 9.
Obesity is a well-established risk factor for pancreatic cancer. Bariatric surgery has demonstrated superior results in terms of weight loss and obesity-related comorbidities compared to medical and behavioral treatments. The aim of this study is to evaluate the effect of bariatric surgery on pancreatic cancer incidence in individuals with obesity.
Individuals with a diagnosis of obesity were retrieved from the French national hospital discharge database. We conducted a cohort study comparing the risk to develop pancreatic cancer in individuals with obesity with and without history of bariatric surgery; the inverse probability of treatment weighting (IPTW) method was performed to assess the uncertainty around the results. Moreover, a subgroup analysis according to age at the time of bariatric surgery was performed to study its impact on the risk of pancreatic cancer. Finally, possible differences depending on the type of bariatric procedure (sleeve gastrectomy vs Roux-en-Y gastric bypass) were also explored.
160,129 (Bariatric Surgery group) and 1,263,804 (control group) patients with 5.2 ± 1.9 and 6.0 ± 1.9 years of follow-up respectively were included. A significant reduced risk to develop pancreatic cancer during follow-up was identified for the bariatric surgery group in the overall population (HR: 0.567). However, this reduced risk was only observed in the 18-50 years group. These results were furtherly confirmed after IPTW analysis. No difference was found between different bariatric procedures.
Bariatric surgery has a protective effect against pancreatic cancer in the 18-50 years population. High-quality prospective studies are needed to confirm these results.
肥胖是胰腺癌公认的危险因素。与药物治疗和行为治疗相比,减肥手术在体重减轻和肥胖相关合并症方面已显示出更好的效果。本研究的目的是评估减肥手术对肥胖个体胰腺癌发病率的影响。
从法国国家医院出院数据库中检索出诊断为肥胖的个体。我们进行了一项队列研究,比较有和没有减肥手术史的肥胖个体患胰腺癌的风险;采用治疗权重逆概率(IPTW)方法评估结果的不确定性。此外,根据减肥手术时的年龄进行亚组分析,以研究其对胰腺癌风险的影响。最后,还探讨了根据减肥手术类型(袖状胃切除术与 Roux-en-Y 胃旁路术)可能存在的差异。
分别纳入了 160129 例(减肥手术组)和 1263804 例(对照组)患者,随访时间分别为 5.2±1.9 年和 6.0±1.9 年。在总体人群中,减肥手术组在随访期间患胰腺癌的风险显著降低(HR:0.567)。然而,这种风险降低仅在 18 - 50 岁组中观察到。IPTW 分析后进一步证实了这些结果。不同减肥手术之间未发现差异。
减肥手术对 18 - 50 岁人群的胰腺癌具有保护作用。需要高质量的前瞻性研究来证实这些结果。